IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
NASDAQ:IDXX • US45168D1046
629.35 USD
+12.15 (+1.97%)
At close: Feb 13, 2026
629.35 USD
0 (0%)
After Hours: 2/13/2026, 8:16:55 PM
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX is not valued too expensively and it also shows a decent growth rate. This makes IDXX very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- In the past year IDXX was profitable.
- In the past year IDXX had a positive cash flow from operations.
- In the past 5 years IDXX has always been profitable.
- In the past 5 years IDXX always reported a positive cash flow from operatings.
1.2 Ratios
- IDXX has a better Return On Assets (30.34%) than 100.00% of its industry peers.
- The Return On Equity of IDXX (65.81%) is better than 100.00% of its industry peers.
- With an excellent Return On Invested Capital value of 40.35%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.75%.
- The last Return On Invested Capital (40.35%) for IDXX is above the 3 year average (37.60%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- With an excellent Profit Margin value of 24.65%, IDXX belongs to the best of the industry, outperforming 95.68% of the companies in the same industry.
- IDXX's Profit Margin has improved in the last couple of years.
- IDXX has a Operating Margin of 31.34%. This is amongst the best in the industry. IDXX outperforms 98.92% of its industry peers.
- In the last couple of years the Operating Margin of IDXX has grown nicely.
- Looking at the Gross Margin, with a value of 61.72%, IDXX is in the better half of the industry, outperforming 64.32% of the companies in the same industry.
- IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- IDXX has less shares outstanding than it did 1 year ago.
- IDXX has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
- IDXX has an Altman-Z score of 21.64. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- IDXX has a Altman-Z score of 21.64. This is amongst the best in the industry. IDXX outperforms 96.22% of its industry peers.
- The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
- IDXX has a better Debt to FCF ratio (1.04) than 90.27% of its industry peers.
- IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.53, IDXX perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.64 |
ROIC/WACC4.05
WACC9.96%
2.3 Liquidity
- IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
- IDXX has a worse Current ratio (1.18) than 81.62% of its industry peers.
- A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.87, IDXX is doing worse than 81.08% of the companies in the same industry.
- The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 16.18% over the past year.
- The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
- The Revenue has grown by 10.42% in the past year. This is quite good.
- Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 9.72% on average per year.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.75% on average per year.
- IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 48.15, IDXX can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 69.73% of the companies listed in the same industry.
- IDXX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.19.
- With a Price/Forward Earnings ratio of 42.48, IDXX can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.65% of the companies listed in the same industry.
- IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.06.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.15 | ||
| Fwd PE | 42.48 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 67.03% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 72.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.45 | ||
| EV/EBITDA | 34.97 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of IDXX may justify a higher PE ratio.
- A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)3.6
PEG (5Y)3.38
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
629.35
+12.15 (+1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change6.88%
Ins Owners0.21%
Ins Owner Change0.68%
Market Cap50.25B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target781.34 (24.15%)
Short Float %2.29%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-0.28%
PT rev (3m)12.01%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.46%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)1.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.15 | ||
| Fwd PE | 42.48 | ||
| P/S | 12.06 | ||
| P/FCF | 53.45 | ||
| P/OCF | 46.19 | ||
| P/B | 32.19 | ||
| P/tB | 48.66 | ||
| EV/EBITDA | 34.97 |
EPS(TTM)13.07
EY2.08%
EPS(NY)14.82
Fwd EY2.35%
FCF(TTM)11.77
FCFY1.87%
OCF(TTM)13.63
OCFY2.17%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.6
PEG (5Y)3.38
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.64 |
F-Score8
WACC9.96%
ROIC/WACC4.05
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 48.15 and the Price/Book (PB) ratio is 32.19.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.